Working... Menu

Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03983096
Recruitment Status : Not yet recruiting
First Posted : June 12, 2019
Last Update Posted : June 12, 2019
CSPC Ouyi Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Tianjin Medical University Cancer Institute and Hospital

No Study Results Posted on for this Study
  Recruitment Status : Not yet recruiting
  Estimated Primary Completion Date : February 1, 2020
  Estimated Study Completion Date : June 1, 2020